Emergent BioSolutions Secures $400 Million in Orders for Smallpox and Mpox Vaccines Amid Ongoing Outbreak
Order Value:
Emergent BioSolutions has secured approximately $400 million in orders for 2024 and 2025 related to its vaccinia, smallpox, and mpox product portfolio.
Delivery Status:
Nearly $210 million in orders have been delivered in 2024, with an additional $185 million confirmed for delivery through 2025.
FDA Approval:
The FDA approved an expanded indication for ACAM2000 to include preventing mpox disease in individuals at high risk for mpox infection.
WHO Submission:
Emergent has submitted an Expression of Interest to the WHO for Emergency Use Listing (EUL) of ACAM2000 for mpox.
Donation:
Emergent has donated 50,000 doses of ACAM2000 for potential deployment in affected African countries.
Company Statement:
Emergent continues to be a trusted partner in supplying medical countermeasures for biodefense and global health preparedness, emphasizing its leadership in addressing serious viral threats like smallpox and mpox.